Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs Mycophenolate Mofetil in Simultaneous Pancreas and Kidney Transplantation to Evaluate Risk of Hernia
2024-517391-38-00Phase 4Authorised
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in end-stage kidney disease (ESKD) and diabetes mellitus type 1 (T1D) comparing Sirolimus (Rapamune) arm with Mycophenolate mofetil arm (2 arms). Primary endpoint: New occurrence of incisional hernia related to the transplantation procedure. Planned start Oct 2024; status: authorised.
02
Drugs
sirolimusmycophenolate mofetil
03
Conditions
end-stage kidney disease (ESKD)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2024-517391-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517391-38-00.